A real-world efficacy study of EyePoint Pharmaceuticals’ Yutiq fluocinolone implant in eyes with chronic noninfectious uveitis demonstrated stable visual acuity trending toward improvement at 6 months, according to a presenter.
“We found it is a convenient and effective adjunct for patients with low-grade chronic uveitis to improve macular edema and allow for further steroid-sparing effect,” Hans W. Andrews, MD, said at the virtual American Academy of Ophthalmology annual meeting.
In a single-center, retrospective, consecutive case series chart review of 103 eyes of 68
Uncategorized